摘要:
The present invention relates to Polycyclic Guanine Derivatives, compositions comprising the Polycyclic Guanine Derivatives and methods of using the Polycyclic Guanine Derivatives to treat pain or an inflammatory disease.
摘要:
The present invention relates to Polycyclic Guanine Derivatives, compositions comprising the Polycyclic Guanine Derivatives and methods of using the Polycyclic Guanine Derivatives to treat pain or an inflammatory disease.
摘要:
The present invention relates to derivatives of 7,8-dihydro-1H-imidazo[2,1-b]purin-4(5H)-one, compositions thereof and methods of use thereof for treating or preventing pain or an inflammatory disease.
摘要:
Disclosed are nociceptin ORL-1 receptor agonists of the formula wherein: (a) R1 is optionally substituted alkyl, fluorenyl, pyrimidinyl or optionally substituted piperidinyl; R2 is H; and R3 is —C(H)(R)—NR7R8; R is H, optionally substituted aryl or arylalkyl, or heteroaryl; R7 is —(CH2)xR9, optionally substituted tetrahydronaphthyl, or cycloalkyl; and R8 is H; or R7 and R8 together form a substituted piperidinyl or piperazinyl ring; x is 0-10; and R9 is H, alkoxy, optionally substituted phenyl, naphthyl, heteroaryl, pyrrolidinyl, pyrrolidonyl, optionally substituted piperidinyl or diphenylmethyl; or (b) R2 is —NHR7 or and R3 is H; pharmaceutical compositions; and methods of using the compounds to treat cough and pain.
摘要翻译:公开了下式的伤害感受肽ORL-1受体激动剂其中:(a)R 1是任选取代的烷基,芴基,嘧啶基或任选取代的哌啶基; R 2是H; 和R 3是-C(H)(R)-NR 7 R 8; R是H,任选取代的芳基或芳烷基或杂芳基; R 7是 - (CH 2 CH 2)x R 9,任选取代的四氢萘基或环烷基; R 8是H; 或R 7和R 8一起形成取代的哌啶基或哌嗪基环; x为0-10; R 9是H,烷氧基,任选取代的苯基,萘基,杂芳基,吡咯烷基,吡咯烷酮基,任选取代的哌啶基或二苯基甲基; 或(b)R 2是-NHR 7或R 3和R 3是H; 药物组合物; 以及使用该化合物治疗咳嗽和疼痛的方法。
摘要:
The invention provides certain 3,7-disubstituted-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-ones of the Formula (I), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R8, and X are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating pain or an inflammatory disease.
摘要:
Hydrophobic peptides having antihypertensive activity are disclosed. Also disclosed are pharmaceutical compositions comprising a hydrophobic peptide and a method of treatment of mammalian hypertension comprising administering a hydrophobic peptide to a hypertensive mammal.
摘要:
Heterocyclic-substituted tricyclics of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein: the single dotted line represents an optional double bond;the double dotted line represents an optional single bond;n is 0-2;Q is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl;Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group;B is --(CH.sub.2).sub.n3 --, wherein n.sub.3 is 0-5, --CH.sub.2 --O--, --CH.sub.2 S--, --CH.sub.2 --NR.sup.6 --, --C(O)NR.sup.6 --. --NR.sup.6 C(O)--, ##STR2## optionally substituted alkenyl or optionally substituted alkynyl; X is --O-- or --NR.sup.6 -- when the double dotted line represents a single bond, or X is --OH or --NHR.sup.20 when the bond is absent;Y is .dbd.O, .dbd.S, (H, H), (H, OH) or (H, C.sub.1 -C.sub.6 alkoxy) when the double dotted line represents a single bond, or when the bond is absent, Y is .dbd.O, (H, H), (H, OH), (H, SH) or (H, C.sub.1 -C.sub.6 alkoxy);R.sup.15 is absent when the double dotted line represents a single bond and is H, --NR.sup.18 R.sup.19, or --OR.sup.17 when the bond is absent; or Y is ##STR3## and R.sup.15 is H or C.sub.1 -C.sub.6 alkyl; are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds.
摘要:
Novel hydrophobic psuedo-peptides of formula I ##STR1## wherein R.sub.1 is lower alkyl or -CH.sub.2 CONR.sub.6 R.sub.7 ; R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are independently lower alkyl, cycloalkyl lower alkyl, aryl lower alkyl, heteroaryl lower alkyl, aryl lower alkoxy, substituted aryl lower alkyl, wherein the aryl portion is substituted with 1-3 substituents independently selected from lowr alkyl, hydroxyl, lower alkoxy and halogeno, substituted heteroaryl lower alkyl wherein the substituents on the heteroaryl portion are as defined for aryl lower alkyl, substituted cycloalkyl lower alkyl, wherein the substituents on the cycloalkyl portion are as defined for aryl lower alkyl, and substituted aryl lower alkoxy wherein the substituents are as defined for aryl lower alkyl;R.sub.6 and R.sub.7 are independently hydrogen or lower alkyl;X.sub.1, X.sub.2, X.sub.3, X.sub.4 and X.sub.5 are independently ##STR2## cis or trans --CR.sub.8 .dbd.CR.sub.9 --, --CHR.sub.8 CHR.sub.9 --, --CH.sub.2 NR.sub.8 --, ##STR3## provided that when R.sup.4 is methyl, X.sub.4 is not --CONH--; R.sub.8 and R.sub.9 are independently hydrogen or lower alkyl;the pharmaceutically acceptable salts thereof,a nd pharmaceutical compositions thereof, useful in the treatment of hypertension are disclosed.
摘要:
Certain substituted sulfonamide quinolines and isoquinolines are disclosed having anti-allergic activity. A preferred use is for the treatment of chronic obstructive lung disease, and in particular, asthma.